ImmuPharma plc (LON:IMM – Get Free Report)’s stock price traded down 10.2% during trading on Friday . The company traded as low as GBX 1.24 ($0.02) and last traded at GBX 1.28 ($0.02). 2,845,345 shares traded hands during trading, an increase of 64% from the average session volume of 1,739,931 shares. The stock had previously closed at GBX 1.43 ($0.02).
ImmuPharma Stock Performance
The firm has a market capitalization of £5.33 million, a P/E ratio of -142.50 and a beta of 1.53. The firm has a 50 day moving average price of GBX 1.74 and a two-hundred day moving average price of GBX 1.87.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Recommended Stories
- Five stocks we like better than ImmuPharma
- Insider Trades May Not Tell You What You Think
- Zeta Global Holdings Insiders Buy Stock After Short-Report
- Investing in Travel Stocks Benefits
- 3 Stocks That Never Lived Up to the Hype
- Options Trading – Understanding Strike Price
- 3 Stocks to Ride the Manufacturing Sector’s Big Comeback
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
